Long-Term Improvements in Patient-Reported Outcomes in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
Kevin H.M. Kuo(University Health Network), Hanny Al‐Samkari(Harvard University), Rachael F. Grace(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Vanessa Beynon(Agios Pharmaceuticals (United States)), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Susanne Holzhauer(Charité - Universitätsmedizin Berlin), Parija Patel(Agios Pharmaceuticals (United States)), Andreas Glenthøj(University of Copenhagen), Eduard J. van Beers(Utrecht University), Junlong Li(First Teaching Hospital of Tianjin University of Traditional Chinese Medicine), Erin Zagadailov(AbbVie (United States))
Cited by 4
Related Papers
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
|The Lancet Haematology|2019|329
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320